ABCL635 aims for a competitive edge by focusing on safety, biomarkers, and once-monthly dosing. ABCL575 offers superior dosing for 3-6 months. Preclinical data and non-human primate studies provide confidence in NK3R engagement translatability.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing